Allergy

Blepharitis

COVID-19

Cataract

Comanagement

Comprehensive Eye Exams

Conjunctivitis

Contact Lenses

Cornea

Diabetic Eye Disease

Dry Eye

Geographic Atrophy

Glasses

Glaucoma

LASIK

Lens Technology

Lid and Lash

Myopia

Nutrition

Ocular Surface Disease

Optic Relief

Patient Care

Pediatrics

Presbyopia

Ptosis

Refractive Surgery

Retina

Technology

Therapeutic Cataract & Refractive

News

All News

Practice Management

Media

All Videos

Expert Interviews

Podcasts

Medical World News

Viewpoints

Insights

Case Based Roundtable Series

Case Studies

Case of the Quarter

Practice Ownership

Rapid Readout

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Conference Recaps

Blog

Publications

Digital Edition

Supplements And Featured Publications

iTech

Partners

Resources

Job Board

Subscribe

Articles

The drops are formulated to target bacteria that cause infections such as bacterial conjunctivitis and otitis externa, or swimmer’s ear.

Bausch + Lomb’s Soothe Antibiotic Drops now available in Canada

CLI Visionaries will be discussing these initial findings during Vision Expo West in the “Shifting Focus: How the Next Generation Sees Contact Lens Wear and Eye Care” panel. 

CLI report underscores unmet potential in Gen Z contact lens wearers

The study compared visual, refractive, and patient-reported outcomes following implantation of enVista Envy and the enVista monofocal intraocular lens (IOL) in cataract surgery patients.

Study assessing Bausch + Lomb's enVista Envy IOLs meets all primary end points

The lens will be available to order on September 17 in the US.

HOYA launches VisuPro lenses for younger presbyopes

Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.

Advertise

About Us

Editorial

Contact Us

Terms & Conditions

Privacy

Do not sell my Information

Optometry Times – Clinical News & Expert Optometrist Insights

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Myopia- Management

1rem

Clinical Focus

Test

How to tailor an eye examination and what technology to consider.

Autism spectrum disorder in children requires patience, flexibility

Phentolamine ophthalmic solution 0.75%, or Nyxol, receives a PDUFA date of September 28, 2023, for the indication of reversal of pharmacologically induced mydrasis.

Ocuphire announced FDA acceptance of NDA for Nyxol for the reversal of mydriasis, sets PDUFA date

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

Ocuphire initiates Global License Agreement for Nyxol eye drops across 3 indications

Thanks for your interest in this podcast. Please read this important program information before listening.

In this podcast, experts John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; and John Hovanesian, MD, FACS; discuss the importance of comprehensive strategies when performing corneal sensitivity testing in patients suspected of having neurotrophic keratitis (NK).

Upon successful completion of this activity, you should be better prepared to:

Summarize the importance of a timely and accurate diagnosis of neurotrophic keratitis

Integrate corneal sensitivity testing into the assessment of ocular surface disease

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Dompé US, Inc; and Brill Engines.

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA

Director, Specialty Contact Lens Division
Cornea and Laser Eye Institute
CLEI Center for Keratoconus
Assistant Clinical Professor, Department of Ophthalmology
Rutgers New Jersey Medical School
Adjunct Clinical Professor, New England College of Optometry
State University of New York College of Optometry
Illinois College of Optometry
Teaneck, NJ

President, Harvard Eye Associates
Specialist in Cornea, External Ocular Disease, Refractive and Cataract Surgery
Clinical Faculty, UCLA Jules Stein Eye Institute
Laguna Hills, CA

AcuFocus, Aerie, Alcon, Allergan, Bausch + Lomb, Cord LLC, EyePoint, Glaukos, Imprimis, Johnson & Johnson Vision, Novartis, Omeros, On Point Vision, Research Insight LLC, Sight Sciences, Sun Pharma, Zeiss;

AcuFocus, Aerie, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, BlephEx, Bruder Healthcare, BVI, Centricity Vision, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, GSK, Hasa Optix, Horizon Therapeutics, Hoya, Imprimis, Johnson & Johnson Vision, Kala, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis, Oyster Point Pharma, Rayner, Research Insight LLC, Sensimed, SightLife, Sun Pharma, Tarsus, TearLab, Thea Pharma, Touch Ophthalmology, Trefoil Therapeutics, Vindico Medical Education, Visus, Zeiss; 

Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Apellis, Bausch + Lomb, BlephEx, Bruder Healthcare, BVI, Cloudbreak Therapeutics, Cord LLC, CorneaGen, Crisper, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Hasa Optix, Horizon Therapeutics, Hoya, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, Orasis, Research InSight LLC, RxSight, Sight Sciences, SightLife, Slack Books, Sun Pharma, Tarsus, Tear Clear, Trefoil Therapeutics, Versant Ventures and its investments, Visionary Ventures Fund 1 and 2 and its investments, Visus, Zeiss.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the latest treatment strategies for patients with neurotrophic keratitis, go to 

https://www.gotoper.com/courses/neurotrophic-keratitis-insights-an-interactive-corneal-sensitivity-testing-workshop

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

In this podcast, Marjan Farid, MD; Beeran Meghpara, MD; and John Hovanesian, MD; review the role of neuromodulation in the pathogenesis of dry eye disease (DED). Additionally, the expert panel discusses a case study of a typical patient presenting with DED and reviews current and newly available treatment options.

Describe the neural network that monitors the ocular surface environment and regulates tear secretion

Assess the mechanisms of action of neuromodulation therapeutics in DED

Evaluate current and emerging therapeutics for DED

Identify clinical applications and patient selection for neuromodulation therapies in DED

This activity is supported by an educational grant from Alcon Vision, LLC.

Professor of Ophthalmology
Director of Cornea, Cataract, and Refractive Surgery
Vice-Chair of Ophthalmic Faculty
University of California, Irvine
Irvine, CA

Marjan Farid, MD, has no financial relationships to disclose.

Clinical Faculty
UCLA Jules Stein Eye Institute
Los Angeles, CA

President
Harvard Eye Associates
Laguna Hills, CA

: AcuFocus, Aerie, Alcon, Allergan, Bausch + Lomb, Cord, EyePoint, Glaukos, Imprimis, Johnson & Johnson Vision, Novartis, Omeros, On Point Vision, Research Insight, Sight Sciences, Sun Pharma, Zeiss; 

: AcuFocus, Aerie, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, BlephEx, Bruder Healthcare, BVI, Centricity Vision, Cloudbreak Therapeutics, Cord, CorneaGen, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, GSK, Hasa Optix, Horizon Therapeutics, Hoya, Imprimis, Johnson & Johnson Vision, Kala, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis, Oyster Point Pharma, Rayner, Research Insight, Sensimed, SightLife, Sun Pharma, Tarsus, TearLab, Thea Pharma, Touch Ophthalmology, Trefoil Therapeutics, Vindico Medical Education, Visus, Zeiss; 

: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Apellis, Bausch + Lomb, BlephEx, Bruder Healthcare, BVI, Cloudbreak Therapeutics, Cord, CorneaGen, Crisper, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Hasa Optix, Horizon Therapeutics, Hoya, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, Orasis, Research InSight, RxSight, Sight Sciences, SightLife, Slack Books, Sun Pharma, Tarsus, Tear Clear, Trefoil Therapeutics, Versant Ventures and its investments, Visionary Ventures Fund 1 and 2 and its investments, Visus, Zeiss.

Clinical Assistant Professor of Ophthalmology
Thomas Jefferson University School of Medicine
Director of Refractive Surgery
Wills Eye Hospital
Philadelphia, PA

: Alcon, Allergan, BioTissue, Dompé, Glaukos, Gore, Johnson & Johnson Vision, Kala, Oculus, Orasis, Sight Sciences, Sun Pharma, Tarsus, Théa, Zeiss; 

Dompé, Johnson & Johnson Vision, Sun Pharma.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

To learn more about this topic, including information on agents targeting neuromodulation in dry eye disease, go 

https://www.gotoper.com/courses/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a

In this podcast, Marjan Farid, MD; Beeran Meghpara, MD; and John Hovanesian, MD; review the role of neuromodulation in the pathogenesis of dry eye disease (DED). Additionally, the expert panel discusses a case study of a typical patient presenting with DED and reviews current and newly available treatment options. 

The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Although neurotrophic keratitis (NK) is considered a rare eye disease, it is a degenerative corneal disease that can profoundly affect patients' lives. Left untreated, NK can lead to corneal ulceration, melting, and perforation, which can ultimately lead to vision loss. In this podcast, experts Quan Dong Nguyen, MD, MSc; and Cecelia Koetting, OD, FAAO, DipABO; discuss the diagnosis, staging, and treatment of NK, focusing on early-stage disease.

This activity is supported by an educational grant from Dompé US, Inc.

Professor of Ophthalmology
Byers Eye Institute, Stanford University School of Medicine
Stanford, CA

 Active Biotech, Genentech, Oculis, Priovant, Regeneron; 

Clinical Instructor
Department of Ophthalmology
University of Colorado School of Medicine
Denver, CO

 KALA BIO, Ocular Therapeutix, Tarsus Pharmaceuticals, Viatris; 

 AbbVie, Alcon, Aldeyra Therapeutics, Azura Ophthalmics, Bausch + Lomb, Blinkjoy, Bruder Healthcare, Dompé US, Glaukos, Myze, Orasis Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Théa Pharma, Topcon Healthcare, Twenty/Twenty, Verséa Ophthalmics, Visus Therapeutics; 

 Alcon, Bausch + Lomb, Dompé US, Glaukos, Harrow, Viatris, Sight Sciences.

In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

This podcast was developed by PER® editorial staff based on an online activity developed with these faculty.

To learn more about this topic, including information on the diagnosis, testing, and management of patients with NK, go to 

https://www.gotoper.com/courses/neurotrophic-keratitis-multidisciplinary-approaches-to-enhance-patient-outcomes

In this podcast, experts Quan Dong Nguyen, MD, MSc; and Cecelia Koetting, OD, FAAO, DipABO; discuss the diagnosis, staging, and treatment of NK, focusing on early-stage disease.

Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

In this podcast, experts Deborah Ristvedt, DO; and Melissa Tawa, OD, FAAO, discuss individualizing glaucoma therapy with selective laser trabeculoplasty and sustained-release drug implants, providing key take-home insights for optimizing glaucoma management across diverse patient profiles.

nontopical therapies available for management of ocular hypertension and open-angle glaucoma, including laser procedures and sustained drug delivery options

the latest advances in minimally invasive glaucoma surgery in appropriate patients

This activity is supported by an educational grant from Glaukos Corporation and Sun Pharmaceutical Industries, Inc.

Anterior Segment Surgeon
Vance Thompson Vision
Alexandria, MN


 AbbVie, BVI Medical, Glaukos, Johnson & Johnson Surgical Vision, RxSight, Sight Sciences; 

 AbbVie, BVI Medical, Glaukos, Johnson & Johnson Surgical Vision, RxSight, Sight Sciences.

Assistant Professor
Southern California College of Optometry
Marshall B. Ketchum University
Anaheim, CA

Melissa Tawa, OD, FAAO, has no relevant financial relationships with ineligible companies.

To learn more about this topic, including information on newer mechanisms of action for topical glaucoma therapies, go to 

https://www.gotoper.com/courses/navigating-the-glaucoma-therapeutic-and-surgical-landscape-from-conventional-to-cutting-edge

Navigating the Glaucoma Therapeutic and Surgical Landscape from Conventional to Cutting Edge

Dry eye disease (DED) is very common among adults; however, it is often undiagnosed and untreated. As DED can have a considerable impact on a patient’s quality of life, early diagnosis and treatment are essential. In this podcast, experts Marc R. Bloomenstein, OD, FAAO; Cory J. Lappin, OD, MS, FAAO; and Selina R. McGee, OD, FAAO, discuss the roles of ophthalmologists and optometrists in managing DED in an evolving treatment landscape, from screening and diagnosis to disease management.

This activity is supported by an educational grant from Bausch + Lomb.

Schwartz Laser Eye Center​
Scottsdale, AZ​

AbbVie; Allergan Aesthetics; Astellas Pharma US; Azura Ophthalmics; Bausch + Lomb; Bruder Healthcare; Dompé US; LENZ Therapeutics; Ocuphire Pharma, Inc; OCuSOFT Inc; Olleyes; Reichert Technologies; Sight Sciences, Inc; STAAR Surgical Company; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Théa Pharma; Topcon Healthcare; Viatris Inc; Visus Therapeutics, Inc. 

 AbbVie; Allergan Aesthetics; Bausch + Lomb; Dompé US; Sight Sciences, Inc; STAAR Surgical Company; Viatris Inc.

Founder​
The Dry Eye Center of Ohio​
Cincinnati, OH​

: Alcon; Barti Software; CSI Dry Eye Software; Eyenovia; Lumenis Be, Inc; MYZE; Nordic Pharma, Inc; NORWOOD Device & Diagnostics; NuLids; PRN Vision Group; Rinsada; SCOPE Health Inc; Tarsus Pharmaceuticals; Viatris Inc; Vital Tears. 

 Bausch + Lomb; Bruder Healthcare; Dompé US; Lumenis Be, Inc; M&S Technologies; 

Barti Software (Investment); MYZE (Medical Advisory Board Member/Investment); NuLids (Investment).

Visionary Founder/Owner​
BeSpoke Vision​
Adjunct Faculty NSUOCO​
Past-President Intrepid Eye Society​
Secretary/Treasurer, Oklahoma Board of Examiners​
Edmond, OK​

AbbVie; Aldeyra Therapeutics, Inc; Alcon; Amgen, Inc; Avellino Lab USA, Inc; Bausch + Lomb; Bruder Healthcare; Carl Zeiss Meditec; Cynosure and Hahn; Dompé US; KALA BIO, Inc; Lumenis Be, Inc; Optovue; RVL Pharmaceuticals, Inc; ScienceBased Health; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Théa Pharma; Topcon Healthcare; Versant; Viatris Inc Health. 

 AbbVie; Alcon; Bausch + Lomb; Cynosure and Hahn; Dompé US; Lumenis Be, Inc; Optovue; ScienceBased Health; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Viatris Inc.

To learn more about this topic, including information on the diagnosis, testing, and management of patients with dry eye disease, go 

https://www.gotoper.com/courses/archived-webcast-interventional-dry-eye-a-stepwise-treatment-and-management-approach

In this podcast, experts Marc R. Bloomenstein, OD, FAAO; Cory J. Lappin, OD, MS, FAAO; and Selina R. McGee, OD, FAAO, discuss the roles of ophthalmologists and optometrists in managing DED in an evolving treatment landscape, from screening and diagnosis to disease management.

Practical Approaches to Modern Dry Eye Treatment and Management

Myopia isn't just a speciality anymore - odds are, you've seen it in your practice. Justin Kwan, OD, FAAO, who is senior manager of myopia management in CooperVision's professional and academic affairs group, shares his journey to passionate myopia management champion in practice and in industry. Drs. Kwan and Korik discuss the minutia of management; talking to parents about myopia control options, how to set fees, and how to get the word out about the new service in your practice.

Prefer to listen on the go? You can follow the podcast on 

Follow Dr Korik on social media:
Instagram: 

https://www.linkedin.com/in/miriam-korik-81b492111/

https://www.youtube.com/channel/UCuIVJVZ17AJFEo8fqXK_gZg

Justin Kwan, OD, FAAO, shares his journey from optometrist to myopia management advocate and provides some tips for getting started on your own journey.

You and Eye: Mastering myopia management - with Justin Kwan, OD, FAAO

Glaucoma remains a leading cause of irreversible blindness globally as progressive optic nerve damage leads to permanent vision loss. Recent advancements in glaucoma management—including novel mechanisms of action, innovative drug delivery systems, and minimally invasive glaucoma surgeries—may help improve adherence, efficacy, and outcomes.

This PER On Air 

 podcast provides an in-depth review of some of the key highlights from the 18th Annual Controversies in Modern Eye Care Conference, held in May 2024. This unique and engaging multi-media activity focuses on the practical aspects of managing patients with glaucoma, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Associate Professor of Ophthalmology and Visual Sciences

Washington University School of Medicine in St Louis

In this episode, four expert faculty talk about the importance of early diagnosis and treatment of thyroid eye disease. They discuss the differential diagnosis, screening tests, and the need for multidisciplinary management for these patients.

Expanding the treatment arsenal in glaucoma management

It's time for back-to-school eye exams, and host Miriam Korik, OD, teams up with Eyes Up host Damaris Raymondi, OD, FAAO, to chat about how to handle pediatric eye exams efficiently, thoroughly, and confidently.

You and Eye: Tips & tricks for streamlined pediatric eye exams - with Damaris Raymondi, OD, FAAO

With dry eye disease (DED) becoming increasingly more prevalent, eye care providers are finding it more important than ever to discuss its side effects and associated risk factors with patients.

A revealing survey released by Bausch + Lomb, the State of Dry Eye, in early July elicited many reactions from practice owners and dry eye experts alike. The survey included participants that have both experienced dry eye symptoms and been diagnosed with DED and those that have not. Data collected from the survey found that not only does dry eye impact quality of life for a majority of those diagnosed, but participants were also largely unaware of the severity and symptoms of dry eye.

Adam Ramsey, OD, of Socialite Vision, said patients may not know the latest information about DED because they try to mitigate their symptoms alone without the recommendations of their eye care provider, or may not be forthcoming about their DED concerns. “Access to care is one of most pivotal parts of eye care that needs to be addressed the most,” he said. “Patients a lot of times feel like they can try and solve their dry eye issues with over-the-counter products alone, but they are quite confused on which ones to use. They’re not sure about the validity, they’re not sure about the success rate of the products that are available to them over-the-counter.”

With 1 of the findings from the survey that dry eye patients feel that they have to give up certain hobbies or daily activities to relieve their dry eye symptoms, Jessilin Quint, OD, MBA, FAAO, of Smart Eye Care, said that education plays an important role to let patients know that changing daily activity may be a last resort. ”That might be true for some occasions, but really that conversation should be with an eye care provider,” she said. “More often than not, with as much innovation and treatment options as we have, you shouldn’t have to give up the things that you love because we do have the tools to manage dry eye”

Gabby Marshall, OD, past president of the Great Western Council of Optometry, said that better public knowledge regarding DED starts with stressing the importance of underlying systemic etiologies to optometric students. “Dry eye disease is often a result of systemic inflammation and while we know that, it's a challenging concept for the public, especially when they want a quick fix,” she said.

Kelly Nichols, OD, MPH, PhD, dean and professor at The University of Alabama at Birmingham School of Optometry, said that the most striking finding was that many patients in the survey experienced dry eye so severe that they could “hear themselves blink.” “This isn’t a symptom we as clinicians query, but I think it is very identifiable to patients,” she said. “In the normal state, there is no awareness of the eyes—you can’t feel them, similar to the lack of awareness when wearing pants or a shirt. But if there is a wound on the arm for example, a shirt would cause a negative sensation. Asking patients if they have awareness of their eyes, and when, may help determine how severe the dry eye might be and what kind of treatment could help.”

Quint said that this finding is also compelling in that some participants treat these symptoms as the norm. “When you think about how that impacts your daily activities and really you shouldn’t have to think about your eyes,” she said. “If anybody has to think about their eyes that’s kind of a red flag that maybe there’s something that we can do there to improve upon things a little bit more.”

Nichols continued on to state that the patients’ inclination to change routines in their daily lives is also telling of the impacts of DED. “While data showing an impact of dry eye on quality of life isn’t new, the high percentage of dry eye patients in this survey (67%) that have changed something, like discontinuing contacts, stopping wearing make-up, or reducing screen time is also something clinicians should ask patients,” she said. “What a patient has given up because of dry eye is just as important as what a patient has tried to treat the condition.”

The survey’s results were released by Bausch + Lomb last month and revealed that many participants did not know their symptoms were dry eye-related.

Comprehensive Eye Exams

Latest News

More News